Searchable abstracts of presentations at key conferences in endocrinology

ea0094p48 | Endocrine Cancer and Late Effects | SFEBES2023

MicroRNA drivers of resistance to androgen deprivation therapy in prostate cancer

Saunders Philippa , Fletcher Claire

Introduction: Prostate cancer is the most prevalent malignancy affecting Western males. Initially an androgen-dependent disease, androgens bind to the androgen receptor and drive expression of genes that promote proliferation and evasion of apoptosis. Although advanced disease involves reduced androgen dependence, androgen receptor signalling remains a key driver of growth. Androgen deprivation therapy (ADT) is first line, but resistance inevitably develops. A...

ea0090oc11.2 | Oral Communications 11: Late Breaking | ECE2023

Machine learning-based steroid metabolome analysis reveals three distinct subtypes of polycystic ovary syndrome and implicates 11-oxygenated androgens as major drivers of metabolic risk

Melson Eka , Rocha Thais P. , Veen Roland J. , Abdi Lida , Mcdonnell Tara , Tandl Veronika , Hawley James M. , Wittemans Laura B.L. , Anthony Amarah V. , Gilligan Lorna C. , Shaheen Fozia , Kempegowda Punith , Gillett Caroline D.T , Cussen Leanne , Missbrenner Cornelia , Lajeunesse-Trempe Fannie , Gleeson Helena , Aled Rees D. , Robinson Lynne , Jayasena Channa , Randeva Harpal S. , Dimitriadis Georgios K. , Gomes Larissa , Sitch Alice J. , Vradi Eleni , Taylor Angela E. , O'Reilly Michael W. , Obermayer-Pietsch Barbara , Biehl Michael , Arlt Wiebke

Introduction: Polycystic ovary syndrome affects 10% of women and comes with a 2-3fold increased risk of type 2 diabetes, hypertension, and fatty liver disease. Androgen excess, a cardinal feature of PCOS, has been implicated as a major contributor to metabolic risk. Adrenal-derived 11-oxygenated androgens represent an important component of PCOS-related androgen excess and are preferentially activated in adipose tissue. We aimed to identify PCOS sub-types with distinct androge...

ea0065oc4.6 | Thyroid | SFEBES2019

Driver events in thyroid cancer recurrence

Nieto Hannah , Thornton Caitlin , Fletcher Alice , Menezes Albert Nobre de , Brookes Katie , Alshahrani Mohammed , Read Martin , Boelaert Kristien , Smith Vicki , Cazier Jean-Baptiste , Mehanna Hisham , McCabe Chris

Thyroid cancer is increasing in incidence worldwide. While outcomes are generally good, up to 25% of patients suffer recurrence, and this has a significant impact on their quality of life and life expectancy. We hypothesised that thyroid tumours which recur display a distinct pattern of driver events, present on initial histology. Controlled-access TCGA data on thyroid cancer were downloaded and whole exome sequencing data analysed. An analysis pipeline utilising Platypus, Ann...

ea0063oc9.3 | Thyroid 2 | ECE2019

Novel driver mutations in thyroid cancer recurrence

Nieto Hannah , Thornton Caitlin , Fletcher Alice , de Menezes Albert Nobre , Baker Kate , Alshahrani Mohammed , Read Martin , Boelaert Kristien , Smith Vicki , Baptiste Cazier Jean , Mehanna Hisham , McCabe Chris

The incidence of thyroid cancer is rapidly increasing worldwide. Whilst outcome in thyroid cancer is generally good, up to 25% of patients develop recurrence, and have a significantly reduced life expectancy. We hypothesise those thyroid tumours which subsequently recur display a distinct pattern of driver events. Whole exome sequencing data were downloaded from The Cancer Genome Atlas (TCGA). Bioinformatic analysis of data on N=43 patients whose tumours recurred was ...

ea0050p383 | Thyroid | SFEBES2017

Novel driver mutations in thyroid cancer recurrence

Nieto Hannah , Fletcher Alice , Thompson Rebecca , Baker Kate , Alshahrani Mohammed , de Menezes Albert Nobre , Read Martin , Boelaert Kristien , Smith Vicki , Cazier Jean-Baptiste , Mehanna Hisham , McCabe Chris

Worldwide, ˜300,000 new cases of differentiated thyroid cancer are reported per annum and thyroid cancer now represents the most rapidly increasing cancer in the US and in the UK. In general terms, outcome is good (10-year survival >90%). However, up to 25% of patients develop local or regional recurrences, and have a significantly reduced life expectancy. We hypothesise those thyroid tumours which subsequently recur display a distinct pattern of driver ...

ea0050p383 | Thyroid | SFEBES2017

Novel driver mutations in thyroid cancer recurrence

Nieto Hannah , Fletcher Alice , Thompson Rebecca , Baker Kate , Alshahrani Mohammed , de Menezes Albert Nobre , Read Martin , Boelaert Kristien , Smith Vicki , Cazier Jean-Baptiste , Mehanna Hisham , McCabe Chris

Worldwide, ˜300,000 new cases of differentiated thyroid cancer are reported per annum and thyroid cancer now represents the most rapidly increasing cancer in the US and in the UK. In general terms, outcome is good (10-year survival >90%). However, up to 25% of patients develop local or regional recurrences, and have a significantly reduced life expectancy. We hypothesise those thyroid tumours which subsequently recur display a distinct pattern of driver ...

ea0042il12 | Castration Resistant Prostate Cancer | Androgens2016

Identifying drivers of disease progression to personalize prostate cancer therapy

Feng Felix Y

We have identified a signature that predicts response to androgen deprivation therapy in localized prostate cancer, and are now using this signature as a stratification variable on biomarker-driven clinical trials. Following up on the Stand-Up-To-Cancer sequencing findings we design a large umbrella trial which will personalize therapy based on actionable genomic alterations in metastatic castration-resistant prostate cancer.DOI: 10.1530/endoabs.42.IL12<...

ea0050s11.1 | New developments in adrenal hypertension | SFEBES2017

ACTH: an underappreciated driver of hypertension

Davies Eleanor

Hypertension is one of the most common risk factors for cardiovascular disease and is well known to have a substantial heritable component. The mineralocorticoid aldosterone plays a key role in the regulation of BP and excess production can lead to hypertension. Therefore, much attention has focused on the genes mediating its biosynthesis.The terminal stage of aldosterone production is catalysed by the aldosterone synthase enzyme, encoded by the CYP1...

ea0050s11.1 | New developments in adrenal hypertension | SFEBES2017

ACTH: an underappreciated driver of hypertension

Davies Eleanor

Hypertension is one of the most common risk factors for cardiovascular disease and is well known to have a substantial heritable component. The mineralocorticoid aldosterone plays a key role in the regulation of BP and excess production can lead to hypertension. Therefore, much attention has focused on the genes mediating its biosynthesis.The terminal stage of aldosterone production is catalysed by the aldosterone synthase enzyme, encoded by the CYP1...

ea0024p52 | (1) | BSPED2010

UK trends in the treatment of young patients with thyrotoxicosis using radioiodine

Turner N , Driver I , Cheetham T

Background: Radioiodine (RI) treatment of benign thyroid disease in young people has received a lot of attention recently with authorities in the US highlighting an encouraging short and medium term safety record. In this audit we surveyed treatment centres in the UK to assess the trend in RI administration in patients aged 21 years and under.Methods: Over sixty Medical Physics Departments, dispersed to represent a suitable geographical coverage pattern ...